Significant association between FOXP3 gene polymorphism and steroid‐resistant acute rejection in living donor liver transplantation

Sapana Verma, Yuka Tanaka, Seiichi Shimizu, Naoki Tanimine, Hideki Ohdan – 8 June 2017 – Previous studies have found that preferential accumulation of regulatory T (Treg) cells in liver allografts during acute cellular rejection (ACR) is associated with less severe rejection, suggesting a role of Treg cells in preventing excessive progress of ACR. We investigated the impact of single nucleotide polymorphisms (SNPs) in the Forkhead box P3 (FOXP3) gene, a master regulator gene of Treg cells, on ACR severity in liver transplant (LT) recipients.

The 28‐year incidence of de novo malignancies after liver transplantation: A single‐center analysis of risk factors and mortality in 1616 patients

Sebastian Rademacher, Daniel Seehofer, Dennis Eurich, Wenzel Schoening, Ruth Neuhaus, Robert Oellinger, Timm Denecke, Andreas Pascher, Eckart Schott, Mariann Sinn, Peter Neuhaus, Johann Pratschke – 7 June 2017 – De novo malignancies (DNMs) are one of the leading causes of late mortality after liver transplantation (LT). We analyzed 1616 consecutive patients who underwent LT between 1988 and 2006 at our institution. All patients were prospectively observed over a study period of 28 years by our own outpatient clinic.

Hepatic artery reconstruction in living donor liver transplantation using surgical loupes: Achieving low rate of hepatic arterial thrombosis in 741 consecutive recipients—tips and tricks to overcome the poor hepatic arterial flow

Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation

Elizabeth M. Brunt – 7 June 2017 – Nonalcoholic fatty liver disease (NAFLD) is one of the most common underlying causes of chronically elevated liver tests and liver disease in adults and children worldwide and may be strongly suspected if not diagnosed by ever evolving and available serologic and imaging‐based noninvasive tests.

Transjugular intrahepatic portosystemic shunt does not independently increase risk of death in high model for end stage liver disease patients

Erin K. Spengler, Lawrence G. Hunsicker, Sanam Zarei, M. Bridget Zimmerman, Michael D. Voigt – 7 June 2017 – Physicians often exclude patients with a model for end‐stage liver disease (MELD) score ≥ 18 from a transjugular intrahepatic portosystemic shunt (TIPS) procedure due to the concern for higher risk of death. We aimed to determine if TIPS increased the risk of death in these patients. We analyzed the interaction between TIPS and MELD in 106 patients with TIPS and 79 with intractable ascites without TIPS.

Beta‐blockers in patients with advanced liver disease: Has the dust settled?

Carlos Moctezuma‐Velazquez, Sylvia Kalainy, Juan G. Abraldes – 7 June 2017 – Nonselective beta‐blockers (NSBBs) have been the backbone for the treatment of portal hypertension in cirrhosis for the last 3 decades. A publication in 2010 of a prospective observational study suggested that NSBBs could increase mortality in patients with refractory ascites. This opened a controversy about the safety and efficacy of NSBBs in patients with advanced liver disease and led to the publication of a large corpus of observational data assessing the safety of NSBBs in patients with advanced cirrhosis.

OSI‐027 modulates acute graft‐versus‐host disease after liver transplantation in a rat model

Xiao Zhi, Fei Xue, Wei Chen, Chao Liang, Hao Liu, Tao Ma, Xuefeng Xia, Liqiang Hu, Xueli Bai, Tingbo Liang – 7 June 2017 – Despite its rarity (1%‐2%), acute graft‐versus‐host disease after liver transplantation (LT‐aGVHD) has a high mortality rate (85%). A gradual decrease in regulatory T cells (Tregs) correlates with disease progression in a rat LT‐GVHD model, and treatments which increase Tregs exert therapeutic effects on LT‐aGVHD. In this study, LT‐aGVHD model rats were treated with rapamycin (RAPA), OSI‐027, or an equal quantity of vehicle.

Subscribe to